To: All County California Children Services (CCS) Program Offices and State Children's Medical Services Branch (CMS) Regional Offices

Subject: Gonadotropin Releasing Hormone (GnRH)-agonist Analogues

The use of GnRH-agonist analogues is a benefit of the CCS Program for those CCS-eligible children with true precocious puberty when all of the following conditions are met.

1. The child is eight years of age or younger (females)/nine years of age or younger (males).

2. There has been rapid advancement, over a period of six months to one year of:
   a. The development of secondary sexual characteristics.
   b. The velocity of growth.
   c. Bone age.

3. There is documentation that the cause of the precocious puberty is central in origin and that peripheral causes of precocious puberty have been ruled out.

4. The recommendation for treatment comes from a CCS-approved Endocrine Center.

Girls nine years and older exhibiting breast development and other early, normal changes of puberty will not be covered.

Maridee A. Gregory, M.D., Chief
Children's Medical Services Branch